EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study

Kazusa Nofuji, Tasuku Mariya iD, Tomohiro Kubo iD, Ayako Murota, Mizue Teramoto, Shutaro Habata, Motoki Matsuura iD, Masahiro Iwasaki, Aki Ishikawa, Kohichi Takada iD, Masashi Idogawa iD, Ichiro Kinoshita iD und 2 weitere

Obstetrics and Gynecology International · 2026-01 · 2026 (1)

DOI: 10.1155/ogi/9990671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obstetrics and Gynecology International, online erschienen am 18.06.2026. Verfasst von Kazusa Nofuji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Personalized medicine utilizing comprehensive cancer genomic profiling (CGP) for gynecologic cancers is still in its early stages and faces numerous challenges. In this study, we aimed to elucidate the current status of CGP for gynecologic cancers at our institution.

Methods

We prospectively analyzed 44 cases of gynecologic cancers that underwent CGP (FoundationOne CDx or Liquid CDx) from March 2020 to July 2022, evaluating the CGP results and clinical outcomes.

Results

Forty‐one cases underwent FoundationOne CDx and four underwent FoundationOne Liquid CDx testing. The distribution of cancer types consisted of 10 cases of cervical cancer, 21 cases of ovarian cancer, 7 cases of endometrial cancer, and 6 cases of sarcomas. Actionable genomic alterations were identified in 42 cases (95.5%), with 16 cases (36.4%) presenting clinically for genotype‐matched therapy (GMT). However, GMT was administered in only three cases (6.8%). Among the cases without GMT, four experienced a deterioration in overall physical condition and two had complications as the reason for nonimplementation. Consideration of presumed germline pathogenic variants occurred in 10 cases (22.2%), with confirmatory testing conducted in two. In survival analysis using the Cox proportional hazards model, the presence of PIK3CA mutations was identified as being potentially associated with adverse prognosis (hazard ratio: 2.73, 95% confidence interval: 1.15–6.49, and p = 0.023).

Conclusion

To enhance the prognosis of gynecologic cases, earlier CGP testing to expand the opportunities for GMT and the proactive introduction of PIK3CA ‐related clinical trials might be crucial.

Schlagwörter

Stichwörter der Autor:innen

cancer genomic profilinggenotype-matched therapygynecologic cancer

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp.
  • Division of Clinical Genomics, Department of Genomic and Preventive Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp.
  • Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp.
  • Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp.
  • Department of Obstetrics and Gynecology, NTT Medical Center Sapporo, Sapporo, Japan.
  • Iwasaki Women's Health Clinic, Tomakomai, Japan.

ORCID-Profile: Tasuku Mariya, Tomohiro Kubo, Motoki Matsuura, Kohichi Takada, Masashi Idogawa, Ichiro Kinoshita

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Nofuji, K., Mariya, T., Kubo, T., Murota, A., Teramoto, M., Habata, S., Matsuura, M., Iwasaki, M., Ishikawa, A., Takada, K., Idogawa, M., Kinoshita, I., Sakurai, A., & Saito, T. (2026). Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study. Obstetrics and Gynecology International, 2026(1). https://doi.org/10.1155/ogi/9990671

Vancouver

Nofuji K, Mariya T, Kubo T, Murota A, Teramoto M, Habata S, et al. Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study. Obstetrics and Gynecology International. 2026;2026(1). doi:10.1155/ogi/9990671

BibTeX
@article{Nofuji2026,
  author = {Nofuji, Kazusa and Mariya, Tasuku and Kubo, Tomohiro and Murota, Ayako and Teramoto, Mizue and Habata, Shutaro and Matsuura, Motoki and Iwasaki, Masahiro and Ishikawa, Aki and Takada, Kohichi and Idogawa, Masashi and Kinoshita, Ichiro and Sakurai, Akihiro and Saito, Tsuyoshi},
  title = {Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study},
  journal = {Obstetrics and Gynecology International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ogi/9990671}
}
Kostenlos starten →